RxDoctor Payments DataLook up a doctor →

James Charles, MD

Neurology · Bayonne, NJNPI 1356457246

Payments from drug & device makers

$127,214in general payments, 2019–2025

Across 1,428 payments — averaging $89.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$35K
  • Amgen$33K
  • Biohaven Pharmaceuticals, Inc.$20K
  • Teva Pharmaceuticals USA, Inc.$16K
  • Biohaven Pharmaceutical Holding Company Ltd.$9K
  • Lundbeck LLC$2K
  • plus $12K from 49 others

What the payments were for

  • Speaking & faculty fees$100,22479%
  • Travel & lodging$3,3023%
  • Food & beverage$23,46018%
  • Education$2280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)280$34,755
Amgen78$33,488
Biohaven Pharmaceuticals, Inc.53$20,426
Teva Pharmaceuticals USA, Inc.144$15,652
Biohaven Pharmaceutical Holding Company Ltd.39$9,016
Lundbeck LLC75$2,201
Supernus Pharmaceuticals, Inc.93$1,578
Amneal Pharmaceuticals LLC75$1,090
Pfizer94$998
EMD Serono, Inc.40$898
Biogen43$856
Axsome Therapeutics, Inc.49$691
Lilly USA, LLC37$496
MDD US Operations, LLC37$443
Novartis41$429
UCB, Inc.29$401
Eisai Inc.16$324
Kyowa Kirin, Inc.21$311
SK Life Science, Inc.17$289
Bristol Myers Squibb16$250
Jazz Pharmaceuticals Inc.8$211
Genentech USA, Inc.7$196
Acadia Pharmaceuticals Inc15$195
Neurocrine Biosciences, Inc.12$192
AstraZeneca11$178
Acorda Therapeutics, Inc5$174
Upsher-smith Laboratories LLC12$174
Banner Life Sciences, LLC1$125
Argenx US, Inc.7$124
Scilex Pharmaceuticals Inc.8$118
Grifols USA, LLC5$91
Merck6$83
GE HealthCare6$79
Impel Pharmaceuticals LLC5$78
Currax Pharmaceuticals LLC5$68
Johnson & Johnson4$56
Collegium Pharmaceutical, Inc.3$43
E.r. Squibb & Sons, L.L.C.3$39
Mallinckrodt Enterprises LLC3$37
Novo Nordisk2$35
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$33
Harmony Biosciences LLC2$30
Avanir Pharmaceuticals, Inc.2$29
Mallinckrodt Hospital Products Inc.2$29
Otsuka America Pharmaceutical, Inc.2$28
Avion Pharmaceuticals2$27
Assertio Therapeutics, Inc.2$26
Adamas Pharmaceuticals, Inc.2$26
TG Therapeutics, Inc.1$22
Vertical Pharmaceuticals, LLC1$15
Almatica Pharma LLC1$15
Tersera Therapeutics LLC1$14
Neurelis, Inc.1$12
Bausch Health US, LLC1$12
Sumitomo Pharma America, Inc.1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$127,214 in reported general payments places this provider in the 90th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$86,281
Medicare patients
152
Services billed
3,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MayzentSiponimod12$133,821
KeppraLevetiracetam16$96,024
Nurtec OdtRimegepant Sulfate57$86,861
NourianzIstradefylline33$78,077
Ajovy AutoinjectorFremanezumab-Vfrm65$60,035
QuliptaAtogepant56$59,733
RytaryCarbidopa/Levodopa87$43,875
UbrelvyUbrogepant31$42,284
Aimovig AutoinjectorErenumab-Aooe46$38,216
FycompaPerampanel24$27,565
XadagoSafinamide Mesylate24$26,190
Dihydroergotamine Mesylate14$24,180
Emgality PenGalcanezumab-Gnlm29$19,861
NeuproRotigotine23$18,970
OngentysOpicapone29$18,962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$429$133,82112 claims
AbbVieQulipta, Ubrelvy$34,755$102,01787 claims
PfizerNurtec Odt, Dilantin$998$89,00068 claims
Kyowa Kirin, Inc.Nourianz$311$78,07733 claims
Amneal Pharmaceuticals LLCRytary$1,090$43,87587 claims
UCB, Inc.Neupro, Briviact$401$36,12036 claims
Eisai Inc.Fycompa$324$27,56524 claims
Neurocrine Biosciences, Inc.Ongentys$192$18,96229 claims
Upsher-smith Laboratories LLCTopiramate$174$81381 claims
Lilly USA, LLCOlanzapine$496$52367 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 521 neurology providers in New Jersey.

Other neurology in Bayonne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →